Wild-type p53 marginally induces endogenous MDR-1 mRNA without causing a measurable drug resistance in human cancer cells

被引:5
|
作者
Nicoletti, MI
Myers, TG
Fojo, T
Blagosklonny, MV
机构
[1] NCI, Med Branch, NIH, Bethesda, MD 20892 USA
[2] NCI, Dev Therapeut Program, NIH, Bethesda, MD 20892 USA
关键词
p53; MDR-1; drug resistance;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The notion that wt p53 downregulates MDR-1 links p53 mutations to multidrug resistant phenotype. Alternatively, it has been envisioned that wt p53 protects cells against DNA damaging drugs by inducing MDR-1. Opposing conclusions on the relationship between MDR-1 and p53 have been predominantly based on the effects of p53 on MDR-1 promoter-constructs. We found that introduction of wt p53 slightly induced MDR-1 mRNA in three cell lines having endogenous mt p53. Wt p53-mediated induction of endogenous MDR-1 may represent a rudiment of cellular protection against toxic compounds earlier in evolution. Marked induction of p21(WAF1/CIP1) (p21) mRNA was observed in all cell lines; and lower levels of wt p53 were required to induce p21 than MDR-1. Pgp was undetectable and wt p53 did not increase resistance to an MDR-1 substrate, suggesting the changes in MDR-1 mRNA may be functionally insignificant. Unlike endogenous MDR-1, the expression of an MDR-1 promoter (-434/+147 fragment) - luciferase construct was unchanged or even inhibited by wt p53 that may be secondary to wt p53-mediated cytotoxicity. Thus, partial promoter constructs may not accurately represent endogenous MDR-1.
引用
收藏
页码:375 / 381
页数:7
相关论文
共 50 条
  • [31] Therapeutic potential of combating cancer by restoring wild-type p53 through mRNA nanodelivery
    Kamath, Divya
    Iwakuma, Tomoo
    Bossmann, Stefan H.
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2024, 56
  • [32] Induction of apoptosis in human lung cancer cells after wild-type p53 activation by methoxyestradiol
    Mukhopadhyay, T
    Roth, JA
    ONCOGENE, 1997, 14 (03) : 379 - 384
  • [33] GROWTH SUPPRESSION OF HUMAN BREAST-CANCER CELLS BY THE INTRODUCTION OF A WILD-TYPE P53 GENE
    CASEY, G
    LOHSUEH, M
    LOPEZ, ME
    VOGELSTEIN, B
    STANBRIDGE, EJ
    ONCOGENE, 1991, 6 (10) : 1791 - 1797
  • [34] Circumvention of drug resistance in human tumors harboring wild-type p53.
    Siddik, Zahid H.
    He, Guangan
    Watanabe, Masayuki
    Mujoo, Kalpana
    Khokhar, Abdul R.
    Kuang, Jian
    CANCER RESEARCH, 2006, 66 (08)
  • [35] Induction of apoptosis in human lung cancer cells after wild-type p53 activation by methoxyestradiol
    Tapas Mukhopadhyay
    Jack A Roth
    Oncogene, 1997, 14 : 379 - 384
  • [36] DIFFERENT SUBNUCLEAR LOCALIZATION OF WILD-TYPE AND MUTANT P53 IN HUMAN PROSTATE-CANCER CELLS
    BURK, U
    SELTER, H
    ZWERGEL, T
    WULLICH, B
    MONTENARH, M
    UNTEREGGER, G
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1995, 7 (06) : 1355 - 1360
  • [37] Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells
    Yang, B
    Eshleman, JR
    Berger, NA
    Markowitz, SD
    CLINICAL CANCER RESEARCH, 1996, 2 (10) : 1649 - 1657
  • [38] Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53
    Sugrue, MM
    Shin, DY
    Lee, SW
    Aaronson, SA
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (18) : 9648 - 9653
  • [39] ENDOGENOUS P53 PROTEIN GENERATED FROM WILD-TYPE ALTERNATIVELY SPLICED P53 RNA IN MOUSE EPIDERMAL-CELLS
    KULESZMARTIN, MF
    LISAFELD, B
    HUANG, H
    KISIEL, ND
    LEE, L
    MOLECULAR AND CELLULAR BIOLOGY, 1994, 14 (03) : 1698 - 1708
  • [40] The Inhibition of Autophagy Sensitises Colon Cancer Cells with Wild-Type p53 but Not Mutant p53 to Topotecan Treatment
    Li, Dan-Dan
    Sun, Ting
    Wu, Xiao-Qi
    Chen, Shu-Peng
    Deng, Rong
    Jiang, Shan
    Feng, Gong-Kan
    Pan, Jing-Xuan
    Zhang, Xiao-Shi
    Zeng, Yi-Xin
    Zhu, Xiao-Feng
    PLOS ONE, 2012, 7 (09):